Beckman coulter life sciences achieves industry-first with commercial release of anti-TRBC2 conjugated antibody for flow cytometry

Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, continues to lead the way with first-to-market concepts to help laboratories achieve goals faster and with greater accuracy. The company today announces it has developed the first commercially available anti-TRBC2 conjugated antibody for flow cytometry, providing greater clarity to clinical researchers in the identification of T-cell neoplasms in areas including cancer research.

Traditional approaches to identify clonal T-cell expansion have been complex and challenging, relying on the assessment of abnormal antigen expression, which is often difficult to clearly identify and can overlap with reactive T-cell subsets. B-cells can offer a richer and more simplistic solution, with the detection of clonal B-cell expansion enabled by the staining of both surface kappa and lambda immunoglobulin light chains utilizing flow cytometry.

The TCR constant β chains 1 and 2, or TRBC1 and TRBC2, are randomly selected during T-cell development in the thymus and are mutually exclusive. Normal T-cell populations include a mix of the two, while clonal populations include only one. TRBC1 and TRBC2 staining using flow cytometry offers a low-cost, rapid, and specific T-cell clonality test. Both can be conjugated to any dye in the Beckman Coulter Life Sciences portfolio through Custom Design Services either as a standalone conjugated antibody, or part of liquid or dry custom panels.

Beckman Coulter Life Sciences has been committed to T-cell research for more than 25 years as we launched our Beta Mark TCR Vβ Repertoire Kit, and we’ve aggressively continued to innovate and raise the bar with solutions for this pioneering method to help labs ensure greater accuracy with fewer touchpoints. This advancement creates a revolutionary step forward in reducing complexities while providing clearer results in the important area of T-cell cancer research.”

Pietro Lopriore, Vice President and General Manager, Flow Cytometry Business Unit

Currently for Research Use Only (RUO), the company is pursuing development of a diagnostic version for commercial availability.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Beckman Coulter Life Sciences. (2024, January 09). Beckman coulter life sciences achieves industry-first with commercial release of anti-TRBC2 conjugated antibody for flow cytometry. News-Medical. Retrieved on April 15, 2024 from https://www.news-medical.net/news/20240109/Beckman-coulter-life-sciences-achieves-industry-first-with-commercial-release-of-anti-TRBC2-conjugated-antibody-for-flow-cytometry.aspx.

  • MLA

    Beckman Coulter Life Sciences. "Beckman coulter life sciences achieves industry-first with commercial release of anti-TRBC2 conjugated antibody for flow cytometry". News-Medical. 15 April 2024. <https://www.news-medical.net/news/20240109/Beckman-coulter-life-sciences-achieves-industry-first-with-commercial-release-of-anti-TRBC2-conjugated-antibody-for-flow-cytometry.aspx>.

  • Chicago

    Beckman Coulter Life Sciences. "Beckman coulter life sciences achieves industry-first with commercial release of anti-TRBC2 conjugated antibody for flow cytometry". News-Medical. https://www.news-medical.net/news/20240109/Beckman-coulter-life-sciences-achieves-industry-first-with-commercial-release-of-anti-TRBC2-conjugated-antibody-for-flow-cytometry.aspx. (accessed April 15, 2024).

  • Harvard

    Beckman Coulter Life Sciences. 2024. Beckman coulter life sciences achieves industry-first with commercial release of anti-TRBC2 conjugated antibody for flow cytometry. News-Medical, viewed 15 April 2024, https://www.news-medical.net/news/20240109/Beckman-coulter-life-sciences-achieves-industry-first-with-commercial-release-of-anti-TRBC2-conjugated-antibody-for-flow-cytometry.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Beckman Coulter Life Sciences presenting at SLAS2023